PATENT CLAIM ANALYSIS

Application Number: 16033636
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2020-01
Patent Classification: ["514", "210180"]

Abstract:
Compounds of structural Formula I were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus, wherein, R 1 , R 2 , R 3 , X and Y are defined in the specification.

Claim (Index 23):
The compound of  claim 22 , wherein:\n R 2  is selected from hydrogen, (C 1  to C 10 ) alkyl, (C 1  to C 10 ) alkenyl, (C 1  to C 10 ) alkynyl, (C 3  to C 10 ) cycloalkyl, (C 5  to C 10 ) cycloalkenyl, (C 1  to C 10 ) alkoxy, \u2014(CH 2 ) n C(O)N(R 11a R 11b ), and \u2014C(O)R 12 , wherein each of the said (C 1  to C 10 ) alkyl, (C 1  to C 10 ) alkenyl, (C 1  to C 10 ) alkynyl, (C 3  to C 10 ) cycloalkyl, (C 5  to C 10 ) cycloalkenyl, and (C 1  to C 10 ) alkoxy is optionally substituted with at least one R 13  group; R 3  is selected from hydrogen, (C 1  to C 10 ) alkyl, (C 1  to C 10 ) alkenyl, (C 1  to C 10 ) alkynyl, (C 3  to C 10 ) cycloalkyl, and (C 5  to C 10 ) cycloalkenyl, wherein each of the said (C 1  to C 10 ) alkyl, (C 1  to C 10 ) alkenyl, (C 1  to C 10 ) alkynyl, (C 6  to C 10 ) cycloalkyl, (C 5  to C 10 ) cycloalkenyl is optionally substituted with at least one R 13  group.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12702937', '13091895', '09669298', '11034635', '13121900']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8023216281064555
- 35 USC 102 Novelty (BERT): 0.5733383191759881
- Combined Prediction Score: 0.7794232972134088
- Mean Citation Score: 332.16656
- Max Citation Score: 360.32703
- Similarity Product: 256.16789312849164

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test